ST Pharm Co Ltd
KOSDAQ:237690
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
60 400
117 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
ST Pharm Co Ltd
Total Assets
ST Pharm Co Ltd
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Total Assets
₩675.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Total Assets
₩16T
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Total Assets
₩171.7B
|
CAGR 3-Years
32%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Total Assets
₩77.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Total Assets
₩189.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
27%
|
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Total Assets
₩20.8B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
ST Pharm Co Ltd
Glance View
Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.
See Also
What is ST Pharm Co Ltd's Total Assets?
Total Assets
675.4B
KRW
Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Total Assets amounts to 675.4B KRW.
What is ST Pharm Co Ltd's Total Assets growth rate?
Total Assets CAGR 5Y
15%
Over the last year, the Total Assets growth was 4%. The average annual Total Assets growth rates for ST Pharm Co Ltd have been 11% over the past three years , 15% over the past five years .
You don't have any saved screeners yet
